Last reviewed: June 8, 2026 Last updated: June 8, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
In addition, semaglutide was associated with a significant 26% reduction in major adverse cardiovascular events compared to placebo in a preapproval cardiovascular outcomes trial (CVOT)
When semaglutide is exposed to temperatures above the recommended storage range, several degradation processes can occur simultaneously
People who experience a semaglutide plateau are often dealing with this exact issue, their metabolism has slowed because they lost too much lean tissue along with fat
Energy levels may start to improve as the body adapts to the medication, and overall health metrics become more stable